LENZ Therapeutics, Inc. (LENZ)
Data as of , from SEC Form 4 filings.
See up to 3 months of LENZ. The 7-day demo opens the 1M and 3M ranges and puts LENZ on your watchlist.
Start 7-day demoLatest LENZ insider trades
Jeffrey P. George - DirectorOpen-market purchase$50K- Evert B. Schimmelpennink - OfficerOpen-market purchase
About LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
- SOLANA BEACH, CA
- 152
- 2024
- XNAS
LENZ Form 4 activity by transaction type, last 90 days
No Form 4 activity for LENZ in the last 90 days.
LENZ insider transactions (Form 4)
5122 Form 4 filings on record, the earliest from Dec 17, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
| Jeffrey P. George - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
 Kimberlee C. Drapkin - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
| James W. McCollum - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
| Shelley B. Thunen - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
 Frederic Guerard - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
| Zachary Scheiner - Director | Grant or award | Stock Option (right to buy) | 22,100 | $0.00 | - | |
| Jeffrey P. George - Director | Open-market purchase | Common Stock | 5,592 | $8.92 footnote F1 | $50K | |
| ||||||
| Evert B. Schimmelpennink - Officer | Open-market purchase | Common Stock | 28,089 | $8.95 footnote F1 | $251K | |
| ||||||
| Daniel R. Chevallard - Officer | Open-market purchase | Common Stock | 7,500 | $8.57 | $64K | |
| Shawn Olsson - Officer | Option exercise | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| Shawn Olsson - Officer | Option exercise | Common Stock | 10,000 | $2.08 | $21K | |
| Shawn Olsson - Officer | Open-market sale | Common Stock | 4,212 | $25.74 footnote F2 | $108K | |
| Shawn Olsson - Officer | Open-market sale | Common Stock | 5,788 | $26.37 footnote F3 | $153K | |
| ||||||
| James W. McCollum - Director | Open-market purchase | Common Stock | 10,500 | $22.79 footnote F1 | $239K | |
| ||||||
| Daniel R. Chevallard - Officer | Open-market purchase | Common Stock | 20 | $22.71 | $454 | |
| Daniel R. Chevallard - Officer | Open-market purchase | Common Stock | 2,178 | $22.76 | $50K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 49,701 | $45.35 | $2.25M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 34,405 | $45.35 | $1.56M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 83,066 | $46.41 | $3.85M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 57,502 | $46.41 | $2.67M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 177 | $47.01 | $8K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 123 | $47.01 | $6K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 49,479 | $41.59 | $2.06M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 24,370 | $41.59 | $1.01M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 40,907 | $43.00 | $1.76M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 20,148 | $43.00 | $866K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 268 | $43.30 | $12K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 132 | $43.30 | $6K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 20,493 | $40.03 | $820K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 10,076 | $40.03 | $403K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 5,668 | $40.59 | $230K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 2,809 | $40.59 | $114K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 50,270 | $39.53 | $1.99M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 24,760 | $39.53 | $979K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 2,149 | $39.92 | $86K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 1,058 | $39.92 | $42K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 43,978 | $38.97 | $1.71M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 21,661 | $38.97 | $844K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 3,465 | $39.50 | $137K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 1,707 | $39.50 | $67K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 145,051 | $39.50 | $5.73M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 69,949 | $39.50 | $2.76M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 30,628 | $38.56 | $1.18M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 15,085 | $38.56 | $582K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 191,376 | $34.00 | $6.51M | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 200,000 | $30.47 | $6.09M | |
| Shelley B. Thunen - Director | Grant or award | Stock Option (right to buy) | 13,500 | $0.00 | - | |
| James W. McCollum - Director | Grant or award | Stock Option (right to buy) | 13,500 | $0.00 | - | |
| Shawn Olsson - Officer | Option exercise | Common Stock | 3,333 | $2.08 | $7K | |
| Shawn Olsson - Officer | Option exercise | Stock Option (right to buy) | 3,333 | $0.00 | - | |
Item 2.02, 9.01
Item 5.02
Item 5.07
Item 2.02, 9.01
LENZ insider trading FAQ
What is the latest insider trade for LENZ?
LENZ Therapeutics, Inc. (LENZ) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-16. The full record for LENZ runs to 22 Form 4 filings, the earliest from 2024-12-17. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LENZ stock?
No insider purchases of LENZ were filed in the last 90 days. 6 purchases are on record for this company.
How many insiders are selling LENZ stock?
No insider sales of LENZ were filed in the last 90 days. 32 sales are on record for this company.
Where can I see LENZ SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LENZ Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - Jeffrey P. George view on EDGAR
- - Kimberlee C. Drapkin view on EDGAR
- - James W. McCollum view on EDGAR
- - Shelley B. Thunen view on EDGAR
- - Frederic Guerard view on EDGAR
- - Zachary Scheiner view on EDGAR
- - Jeffrey P. George view on EDGAR
- - Evert B. Schimmelpennink view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where LENZ's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LENZ with a 7-day demo
- LENZ on your watchlist
- Every LENZ Form 4 filing on record
- Up to 3 months of LENZ price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
